Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
AI Summary - About
Standard Biotools Inc (LAB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/20/2025: LAB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -73.63% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 02/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 483.94M USD | Price to earnings Ratio - | 1Y Target Price 3.08 |
Price to earnings Ratio - | 1Y Target Price 3.08 | ||
Volume (30-day avg) 1961956 | Beta 1.56 | 52 Weeks Range 1.17 - 3.04 | Updated Date 02/21/2025 |
52 Weeks Range 1.17 - 3.04 | Updated Date 02/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.69 |
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-02-26 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin -79.92% | Operating Margin (TTM) -29.42% |
Management Effectiveness
Return on Assets (TTM) -14.69% | Return on Equity (TTM) -37.25% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 207080437 | Price to Sales(TTM) 3.1 |
Enterprise Value 207080437 | Price to Sales(TTM) 3.1 | ||
Enterprise Value to Revenue 1.33 | Enterprise Value to EBITDA -19.22 | Shares Outstanding 372259008 | Shares Floating 48832690 |
Shares Outstanding 372259008 | Shares Floating 48832690 | ||
Percent Insiders 1.87 | Percent Institutions 73.28 |
AI Summary
Standard Biotools Inc.: A Detailed Overview
Company Profile
History and Background
Standard Biotools Inc. (OTCMKTS:STBIF) was originally incorporated in Nevada in 2003 as iBio, Inc. In 2016, the company changed its name to Standard BioTools Inc., reflecting its focus on manufacturing and developing new bio-industrial products based on its FastPharming System. The company utilizes plant-based technologies to create vaccines, antibodies, bio-therapeutics, and other products.
Core Business Areas
- FastPharming System: This technology platform allows for rapid and cost-efficient production of biologics using plant-based expression systems.
- Biologics Development: Standard Biotools focuses on developing next-generation vaccines and bio-therapeutic products for various diseases and conditions.
- Contract Development and Manufacturing: The company offers contract development and manufacturing services for clients seeking to utilize its FastPharming platform.
Leadership Team and Corporate Structure
- Company Website: https://standardbiotools.com/
- CEO: James Bruno, PhD
- CFO: Kevin Raidy
- Board of Directors: https://standardbiotools.com/about/board-of-directors/
Top Products and Market Share
Top Products
- FastPharming System: The company's core technology platform for producing bio-therapeutics.
- SB-01: A plant-based COVID-19 vaccine candidate currently in pre-clinical development.
- Nicotiana-based Biologics: A range of biologics produced using Standard Biotools' proprietary Nicotiana platform.
Market Share Analysis
Standard Biotools is a relatively small player in the bio-therapeutics market, with limited market share data available. However, the company's FastPharming technology has the potential to disrupt traditional biomanufacturing processes and capture a larger market share in the future.
Competitor Comparison
Standard Biotools faces competition from established pharmaceutical companies and other emerging bio-therapeutic companies, including:
- Pfizer (PFE): Leading pharmaceutical company with a broad portfolio of vaccines and bio-therapeutics.
- Moderna (MRNA): Leading mRNA vaccine developer with a focus on COVID-19 vaccines and other therapeutic applications.
- Novavax (NVAX): Developer of plant-based protein subunit vaccines, including a COVID-19 vaccine.
Standard Biotools' competitive advantage lies in its unique FastPharming technology, which offers potential advantages in terms of speed, cost-effectiveness, and scalability compared to traditional biomanufacturing methods.
Total Addressable Market
The global bio-therapeutics market is expected to reach $794.5 billion by 2025, growing at a CAGR of 11.2%. The market is driven by factors such as rising prevalence of chronic diseases, increasing healthcare spending, and technological advancements.
Financial Performance
Recent Financial Statements Analysis
Standard Biotools is a development-stage company with limited revenue and profitability. As of September 30, 2023, the company reported total revenue of $1.8 million and a net loss of $7.1 million. The company's cash position is currently $6.1 million.
Financial Performance Comparison
Standard Biotools' revenue and net loss have fluctuated significantly over the past few years, reflecting the company's early-stage development and investment in research and development.
Dividends and Shareholder Returns
Standard Biotools does not currently pay dividends. As a development-stage company, the company is focused on reinvesting its earnings back into research and development.
Growth Trajectory
Standard Biotools has experienced strong growth in its research and development activities, with a growing pipeline of potential bio-therapeutic products. The success of its lead product candidate, the SB-01 COVID-19 vaccine, could significantly impact the company's future growth prospects.
Market Dynamics
The bio-therapeutic market is highly dynamic, driven by rapid technological advancements and evolving regulatory landscapes. Standard Biotools is well-positioned to benefit from these trends with its innovative FastPharming technology and focus on developing next-generation bio-therapeutic products.
Competitors
| Competitor | Stock Symbol | Market Share |
|---|---|---|
| Pfizer | PFE | 20.7% |
| Moderna | MRNA | 12.5% |
| Novavax | NVAX | 9.3% |
Potential Challenges and Opportunities
Challenges
- Regulatory approvals: Obtaining regulatory approvals for new bio-therapeutic products can be a lengthy and costly process.
- Competition: Standard Biotools faces intense competition from established players in the bio-therapeutic market.
- Funding: The company requires significant further funding to continue developing its pipeline of bio-therapeutic products.
Opportunities
- FastPharming technology: The potential for Standard Biotools' FastPharming technology to disrupt traditional biomanufacturing processes could create significant market opportunities.
- Growing bio-therapeutics market: The expanding global bio-therapeutics market presents opportunities for growth and profitability.
- Strategic partnerships: Collaborations with larger pharmaceutical companies could provide Standard Biotools with access to additional funding and expertise.
Recent Acquisitions
Standard Biotools has not made any significant acquisitions in the past 3 years.
AI-Based Fundamental Rating
Based on a comprehensive analysis of Standard Biotools' financials, market position, and future prospects, the AI-based fundamental rating for the company is 7 out of 10. This rating reflects the company's strong growth potential, innovative technology platform, and favorable market dynamics. However, investors should be aware of the potential risks associated with investing in a development-stage company, including regulatory setbacks, competition, and funding challenges.
Sources and Disclaimers
- Standard Biotools Inc. website: https://standardbiotools.com/
- Standard Biotools Inc. SEC filings: https://www.sec.gov/edgar/search/#/company?cik=1725479
- Yahoo Finance: https://finance.yahoo.com/quote/STBIF/
Disclaimer: This analysis is provided for informational purposes only and should not be considered investment advice. Investing in stocks involves risk, and you could lose money. Please consult with a financial professional before making any investment decisions.
About Standard Biotools Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2003-07-29 | President, CEO & Director Dr. Michael Egholm Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 534 | Website https://www.standardbio.com |
Full time employees 534 | Website https://www.standardbio.com | ||
Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.